after enrollment, baseline measurements are taken. the first administration of aspaveli (pegcetacoplan) is given as a subcutaneous injection. the solution contains a dose of 308.6 mg.

subcutaneous means the medication is injected just under the skin.

subsequent doses of aspaveli are administered according to the schedule defined by the study protocol. the exact frequency and duration are not specified in the provided information.

approximately one month after the first dose, a clinic visit is scheduled.

laboratory tests are performed, including measurement of upcr (urine protein‑to‑creatinine ratio) and egfr (estimated glomerular filtration rate). questionnaires about fatigue and work productivity may be completed.

at three months, another assessment is performed.

the same laboratory tests as at month 1 are repeated, and any changes in kidney biopsy findings or other biomarkers are recorded.

at six months, the primary outcome is evaluated: achieving an upcr of less than 1 g/g.

additional measurements of proteinuria, kidney function, and safety parameters are collected.

at twelve months, a comprehensive review is conducted.

laboratory values, kidney function, and patient‑reported outcomes are compared with baseline values.

after the first year, visits continue every six months for the remainder of the study.

each visit includes laboratory tests (upcr, egfr), safety assessments, and questionnaires.

if a change in treatment is required, the study records the reason, the new dose, and the timing of the change.

possible changes include dose reduction, temporary interruption, restart of pegcetacoplan, or switch to another complement inhibitor such as iptacopan.

at the end of the study period, final data on kidney function, proteinuria, safety events, and quality‑of‑life measures are collected.

the information is used to evaluate the overall effectiveness and safety of pegcetacoplan in patients with c3g or ic‑mpgn.